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SUMMARY 
 
Turmeric (Curcuma longa ) is a medicinal plant of the family 
Zingiberaceae widely growing throughout India. Turmeric oil is 
secondary metabolite of turmeric and obtained by steam distillation of 
its rhizomes. Turmeric oil a lipophilic fraction from turmeric, exhibits 
several therapeutic potentials. Turmeric oil chiefly comprises ar-
turmerone and β-turmerone. During more recent decades broad 
spectrums of therapeutically interesting pharmacological properties of 
turmeric and its secondary metabolites have been reported. Recent 
several efforts made to explore the pharmacological profile and 
mechanism of action of turmeric revealed exceptionally broad 
spectrums of pharmacological activity profiles of turmeric oil. It is 
now well recognized that additive or synergistic interactions between 
diverse combinations of phytochemicals are involved in health 
benefits of vegetarian diets and herbal remedies and that regular 
consumption of appropriate combinations of some such edible 
phytochemicals with every day meals could as well be used for 
prevention and cure of different health problems. Critical analysis of 
available preclinical and clinical information on turmeric oil strongly 
suggests it is pharmacologically polyvalent and possess several 
pharmacological properties. Aim of this communication is to 
summarize and critically analyze such data, and to point out some 
possibilities for more rationally exploiting their therapeutic potential 
for discovering novel therapeutic leads, or for obtaining 
pharmacologically better standardized phyto-pharmaceuticals. 
 
Ključne reči:Curcuma longa, Turmeric oil, lipophilic, phyto-pharmaceuticals. 
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INTRODUCTION 
 
Essential oils are complex mixtures of volatile terpenes selected throughout 
evolution to protect plants from external threats by various means including 
mimicking endogenous substrates in herbivores. While biologic and potentially 
medicinal effects of these essential oils are thus to be anticipated, these compounds 
are often less well studied than other classes of secondary plant metabolites, with 
polyphenols being a prominent example. Such is the case for turmeric (Curcuma 
longa  L., Zingiberaceae), a medicinal botanical whose rhizome contains two major 
classes of secondary metabolites, the phenolic curcuminoids and the hydrophobic 
essential oils. Turmeric (Curcuma longa  L.) is one of the most widely used ancient 
herbs, which is traditionally used in several Asian countries for several 
inflammatory, infectious, fungal and viral ailments. Various preparations derived 
from turmeric display potential therapeutic effects against cancer, pains, stomach 
upset, ulcer, dysentery and wounds [1]. Turmeric oil is prepared from the rhizome 
of turmeric by steam distillation [2]. Turmeric oil is different from oleoresin of 
turmeric where curcuminoids are the major compounds while ar-turmerone is the 
major constituent of turmeric oil [3]. Several medicinal and pharmacological 
properties such as antifungal, insect repellent, anti-bacterial, anti-platelet and anti-
mutagenic activities of turmeric oil have been reported [4-6]. Turmeric oil also 
possess anti-inflammatory, antioxidant, anti-arthritic and antinociceptive properties 
[7]. It has shown efficacy in neuroprotective activity against cerebral ischemia and 
attenuation of delayed neuronal death via a caspase dependent pathway [8-10]. The 
chemopreventive efficacy of turmeric oil has been reported against submucous 
fibrosis in humans [11]. It also acts against benzo [α] pyrene induced DNA damage 
in vitro in oral mucosa cells [12]. Since turmeric oil is highly lipophilic in nature its 
accessibility to the brain is facilitated and has been found to be protective against 
stroke [13]. Thus, further evaluations against various biological activities, 
fractionation and identification of the mechanism of action prior its therapeutic 
uses are needed.  
Turmeric oil also can improve the bioavailability of curcumin after oral 
administration in humans [14]. Food and Drug Administration (FDA) approved 
turmeric oil as food additive mentioned as safe drug. There is considerable 
evidence that the antioxidants contained in fruits; vegetables and beverages play an 
important role in the maintenance of health, and in prevention of disease. The 
safety of synthetic antioxidants, such as butylated hydroxyanisole, butylated 
hydroxytoluene and propyl gallate, is now under scrutiny [15]. Thus, the food 
industry is undertaking the rapid development and use of natural antioxidants, 
especially those of plant origin, to replace synthetic food additives. Among these 
various kinds of natural substances, essential oils from aromatic and medicinal 
plants receive particular attention as potential natural agents for food preservation.  
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PHYTOCHEMICAL CONSTITUENTS 
 
Turmeric oil is isolated by steam distillation from the rhizome of turmeric. 
The color and appearance of turmeric oil is pale yellow liquid and store at 4 °C 
away from direct light. GC– MS indicate that the main components of turmeric oil 
are ar-turmerone (61.79%) and curlone (β- turmerone) (12.48%). Other major and 
minor ingredients in this essential oil are ar-curcumene (6.11%), phenol (3.45%), 
zingiberene (2.98%), α-sesquiphellandrene (2.81%), 1-ethyl- 4-isobutylbenzene 
(2.62%), β–bisabolene (1.48%), benzene (1.48%), benzaldehyde (1.44%), 1,2,3,5-
tetramethyl-benzene (1.42%), silane (0.84%), and 4-methyl-carbanilonitrile 
(1.09%) some other constituents are ar-turmerol, caryophyllen oxide, d-3-carene, 
α-phellandrene (Fig.1) [2, 4, 17].  
 
 
THERAPEUTIC INDICATIONS 
 
Antimutagenic activity 
Reported biologic properties of the multi-component essential oils of 
turmeric include antimutagenic and anticarcinogenic activity. Turmeric oil showed 
significant antimutagenic activity against direct acting mutagens such as sodium 
azide, 4-nitro-O-phenylenediamine and N-methyl- N-nitro N’nitrosoguanine. 
Turmeric oil is found to have significant antimutagenic effect against mutagen 
needing metabolic activation such as 2-acetamidoflourene. Turmeric oil 
significantly inhibited the mutagenicity induced by tobacco extract to Salmonella 
strain. DMBA and croton oil induced papilloma development in mice was found to 
be delayed and prevented significantly by turmeric oil application. Moreover, 
turmeric oil significantly inhibited isoforms of cytochrome p450 (CYP1A1, 
CYP1A2, CYP2B1/2, CYP2A, CYP2B and CYP3A) enzymes in vitro, which are 
involved in the activation of carcinogens [18]. Some such therapeutically 
interesting bioactivities of turmeric oil are summarized in Table 1 and Fig. 2. 
 
Neuroprotective activity 
Turmeric oil ameliorates the ischemia induced neurological functional 
deficits, infarct and edema volumes measured after 24 hrs of ischemia. 
Immunohistochemical and Western blot analysis demonstrated that the expression 
of iNOS, cytochrome c and Bax/Bcl-2 were altered after the insult and antagonized 
by treatment with turmeric oil. Turmeric oil significantly reduces nitrosative stress; 
it tends to correct the decreased mitochondrial membrane potential and also affects 
caspase-3 activation [9]. Turmeric oil reduced post-ischemic brain neutrophil 
infiltration in the ischemic area, controlled tissue nitric oxide levels and the 
neuronal levels of nitric oxide, peroxynitrite and reactive oxygen species. Double  
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Table 1. Some reported pharmacological activities of Turmeric oil. 
Tabela 1. Publikovani podaci o farmakološkoj aktivnosti etarskog ulja kurkume. 
 
Pharmacological 
activities 
Dose duration and  
route of administration References 
Anti-inflammatory 
activity 100, 500 & 1000 mg/kg, 5 days, i.p. [2] 
Antioxidant activity 100 & 500 mg/kg, 30 days, p.o. [2] 
Antinociception activity 100, 500 &1000 mg/kg, 1 days, i.p. [2] 
Neuroprotective 250 & 500 mg/kg, 1 day, p.o. [9,19] 
Anti-hyperlipidaemic 30, 100 & 300 mg/kg, 28 days, p.o. 100 & 300 mg/kg, 45 days, p.o [20,21] 
Anti atherosclerosis 100  & 300 mg/kg, 7 days, p.o. [22] 
Antiarthritic activity 56 mg/kg, 10 days,  i.p. [7] 
Anti-ischemic 500 mg/kg, 3 days, p.o. [6] 
Antiplatelets 500 mg/kg, 3 days, p.o. [6] 
Liver cirrhosis 100, 200 & 500 mg/kg, 2 weeks, i.p. [24] 
Antifibrosis 100 & 300 mg/kg, 7 days, i.p. [25] 
Disease modifying 
activity 300 mg/kg, 4 weeks, p.o. [23] 
Cytoprotective 600 mg/kg, 3 months, p.o. [12] 
Anti-apoptogenic 500 mg/Kg, 5 days, i.p. [10] 
Antifungal 459 µg/ml in vitro [26] 
Antibacterial activity 50, 100 & 200 ppm in vitro [4] 
Antidermatophytic 312 ?g/mL in vitro [27] 
Antiaflatoxigenic 
activity 0.01–5% (v/v) in vitro [28] 
Chemopreventive 50, 100 and 200 μg/ml in vitro [18] 
Superoxide radical 
scavenging activity 
135 µg/ml in vitro 
22.6–45.27 µg/ml  in vitro [2,29] 
Hydroxyl radical 
scavenging activity 
200 µg/ml in vitro 
18.27 μg/ml in vitro [2,29] 
Inhibition of lipid 
peroxidation 400 μg/ml in vitro [2] 
DPPH radical 
scavenging activity 
1000 μg/ml in vitro 
14.45 & 16.58 µg/ml in vitro [2,29] 
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glutathione peroxidase and lowered maleic dialdehyde activity, to suppress oxidative 
reactions. Besides, histological morphology examination showed that turmeric oil 
also prevented the damage of liver tissues induced by high fat diet [21].  
 
Anti atherosclerotic activity 
Turmeric oil attenuates arterial injury-induced accelerated atherosclerosis, 
inflammation and macrophage foam-cell formation [22]. The administration of 
turmeric oil suppressed the mRNA expression of TNF-α, IL-1β, IL-6 and IFN-γ 
and increased the expression of TGF-β in peritoneal macrophages. In THP-1 
macrophages, turmeric oil supplementation prevented oxidized low density 
lipoprotein induced production of TNF-α and IL-1β and increased the levels of 
TGF-β. The above mentioned study shows that turmeric oil attenuates arterial 
injury-induced accelerated atherosclerosis, inflammation and macrophage foam-
cell formation. 
 
Disease modifying activity 
Turmeric oil treatment in hamsters ameliorated hyperlipidaemia, 
hyperglycaemia, insulin resistance, oxidative stress, inflammation, endothelial 
dysfunction, platelet activation, and thrombosis. Turmeric oil treatment also in rats 
ameliorated hyperglycaemia and hyperinsulinaemia by modulating hepatic 
expression of sterol regulatory element binding protein 1c, peroxisome proliferator 
activated receptor gamma co-activator-1α and peroxisome proliferator activated 
receptor gamma co-activator-1β genes known to be involved in lipid and glucose 
metabolism. High fructose feeding to rats and hamsters led to the development of 
insulin resistance, hyperglycaemia, endothelial dysfunction and oxidative stress. 
Turmeric oil also prevented development of thrombotic complications associated 
with insulin resistance perhaps by modulating genes involved in lipid and glucose 
metabolism [23]. 
 
Anti-arthritic activity 
Another study of turmeric oil explored its anti-arthritic effect in female 
rats. It dramatically inhibited joint swelling in female rats with streptococcal cell 
wall induced arthritis. Oral administration of higher dose turmeric oil was non-
toxic, but only mildly joint protective. These results do not support the isolated use 
of turmeric oil for arthritis treatment, but instead, identify potential safety concerns 
in vertebrates exposed to turmeric oil [7]. 
 
Anti-ischemic activity 
Turmeric oil at 500 mg/kg dose was evaluated against myocardial 
ischemia-reperfusion induced injury in the rat model. Turmeric oil failed to confer 
protection against cardiac injury, however significant reversal of ADP induced 
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platelet aggregation was evident in the same animals. Moreover, collagen and 
thrombin induced platelet aggregation as well as tyrosine phosphorylation of 
various proteins in activated platelets was also suppressed. Turmeric oil also 
offered significant protection against collagen-epinephrine induced thrombo 
embolism in mice as well as augmented total time to occlusion against FeCl3 
induced arterial thrombosis in rats [6]. 
 
Hepatoprotective activity 
Turmeric oil was found to reverse those changes of serum levels observed 
in the cirrhotic rats and the 200 mg/kg treated group showed the most obvious 
reverse tendency with significantly decreased alanine amino transferase, aspartate 
aminotransferase and increased albumin levels. The results indicated that turmeric 
oil with the dose of 100 mg/kg could inhibit the activities of CYP450 isoforms 
CYP2C9 and CYP2D6 in vivo in cirrhotic rats, while dose of 400 mg/kg could 
induce the activity of CYP2C19 [24]. 
 
Antifibrosis activity 
Turmeric oil also demonstrating protective and anti-fibrosis activities in 
renal fibrosis. Nuclear magnetic resonance based metabonomics combined with 
clinical chemistry and histopathology examination were performed to evaluate 
intervening effects of Turmeric oil on renal interstitial fibrosis rats induced by 
unilateral ureteral obstruction. The metabolite levels were compared based on 
integral values of serum 1H NMR spectra from rats on 3, 7, 14, and 28 days after 
the medicine administration. Time trajectory analysis demonstrated that metabolic 
profiles of the agent treated rats were restored to control levels after 7 days of 
dosage. The results confirmed that the agent would be an effective anti-fibrosis 
medicine in a time-dependent manner, especially in early renal fibrosis stage. The 
results of some other study substantiated that turmeric oil administration can 
ameliorate renal fibrosis symptoms by inhibiting some metabolic pathways, 
including lipids metabolism, glycolysis and methylamine metabolism [25]. 
 
Antidermatophytic activity 
Turmeric oil was studied against fifteen isolates of dermatophytes, four 
isolates of pathogenic molds and six isolates of yeasts. The inhibitory activity of 
turmeric oil was tested in Trichophyton-induced dermatophytosis in guinea pigs. 
The results showed that all 15 isolates of dermatophytes could be inhibited by 
turmeric oil at dilutions of 1:40-1:320. The other four isolates of pathogenic fungi 
were inhibited by turmeric oil at dilutions of 1:40-1:80. In the experimental 
animals, turmeric oil (dilution 1:80) was applied by dermal application on the 7th 
day following dermatophytosis induction with Trichophyton rubrum. An 
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improvement in lesions was observed in 2-5 days and the lesions disappeared 6-7 
days after the application of turmeric oil [26]. 
 
Antibacterial activity 
The mother liquor after isolation of curcumin from oleoresin contains 
approximately 40% oil. The oil was extracted from the mother liquor using hexane 
and the hexane extract was separated into three fractions using silica gel column 
chromatography. These fractions were tested for antibacterial activity by pour plate 
method against Bacillus cereus, Bacillus coagulans, Bacillus subtilis, 
Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Fraction 
eluted with 5% ethyl acetate in hexane was found to be most active fraction for the 
antibacterial activity [4]. 
 
Antifungal activity 
Some previous studies on turmeric oil reported effective antifungal activity 
against dermatophytes, a group of fungi that causes skin diseases. In mentioned 
study turmeric creams containing 6 and 10% w/w turmeric oil were prepared and 
tested against clinical strains of dermatophytes using broth dilution technique. 
Minimum fungicidal concentrations of turmeric creams were found to be 312 
?g/mL. Ar-turmerone, a major compound separated from turmeric oil, promoted 
more effective antidermatophytic activity with the MICs of 1.56–6.25 ?g/mL, 
compared to 3.90–7.81 ?g/mL of standard ketoconazole. The results indicated that 
turmeric oil in the cream was suitable to be formulated as antidermatophytic 
preparation [27].Some other pharmacological properties of ar-turmerone are 
summarized in Table 2.  
 
Table 2. Some reported pharmacological activities of ar-turmerone. 
Tabela 2. Publikovani podaci o farmakološkoj aktivnosti ar-turmerona. 
 
Pharmacological 
activities 
Dose, duration and 
route of administration References 
Antidepressant 2.5 and 5.0 mg/kg, 7 days, p.o. [34] 
Antiepileptic 50 mg/kg, single dose, i.p. [39] 
Antidermatophytic 1.56-6.25 ?g/ml in vitro [27] 
Antitumor activity 200 and 300 mg/kg, 10 days, p.o. 20-50 µg/ml in vitro [30,40] 
Antidiabetic 20-100 mg/kg, 4 weeks, p.o. [32] 
Antiplatelet activity 10 and 100 μg/ml in vitro [33] 
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Antiaflatoxigenic activity 
Aflatoxins are highly toxic, mutagenic, teratogenic and carcinogenic 
mycotoxins. Consumption of aflatoxin contaminated food and commodities possess 
serious hazards to the health of humans and animals. Turmeric oil also contains the 
antiaflatoxigenic activities. According to mentioned report medium tests were 
prepared with the turmeric oil at concentrations varied from 0.01% to 5.0%. All 
doses of the essential oil of the plant interfered with mycotoxin production. 
Turmeric oil significantly inhibited the production of aflatoxins; the 0.5% level had 
a greater than 96% inhibitory effect. The levels of aflatoxin B1 production were 
found to be 1.0 µg/mL, for the samples treated with the turmeric oil at a 
concentration of 0.5% [28]. 
 
Antioxidant activity 
The antioxidant activity of the oil was evaluated by using 2, 2- diphenyl-1-
picrylhydrazyl (DPPH) and superoxide radical-scavenging assays. The oil showed 
potent DPPH radical-scavenging activity (IC50 = 14.45 µg/ml), which was higher 
than butylated hydroxyanisole (IC50 = 18.27 µg/ml). The results indicate that the 
turmeric oil could serve as an important bio-resource of antioxidants for using in the 
food industries [29]. In an another study turmeric oil was found to have in vitro 
antioxidant activity and IC50 for scavenging superoxides, hydroxyl radicals, and lipid 
peroxidation were 135 μg/ml, 200 μg/ml, and 400 μg/ml, respectively. The ferric-
reducing activity for 50 μg of turmeric essential oil was found to be 5 mM. 
Intraperitoneal administration of oil was found to inhibit PMA-induced superoxide 
radicals elicited by macrophages. However, oral administration of turmeric oil for 
one month to mice significantly increased superoxide dismutase, glutathione, and 
glutathione reductase enzyme levels in blood and glutathione-S-transferase and 
superoxide dismutase enzymes in liver [2]. Therefore, results demonstrated that 
turmeric oil could be use for potential health benefits as it is potent antioxidant in 
nature. 
 
Antiapoptic activity 
Major constituent of turmeric oil ar-turmerone found to be antiapoptic in 
nature. It inhibited the increase in the number of white blood cells, which normally 
increase by the injection of lymphoblast cells, or P388D1, and increased lymphocyte 
percentage compared to the control. Tumor inhibi¬tion rate in the ar-turmerone 
treated group was 11.79%, and the apoptosis indexes of the control and ar-turmerone 
were 4.22±1.02 and 5.45±1.46 respectively [30]. It shown that ar-turmerone has a 
repressive effect on P388D1 lymphocytic leukemia. It is also suggested that this 
protective effect of ar-turmerone from P388D1 lymphocytic leukemia resulted from 
the increased activity of tumor immunogenicity through increased T-lymphokine 
production and increased percentage of lymphocytes. Another report based on 
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pharmacological profile of ar-turmerone, the major compound present in turmeric oil 
also shown to exhibit its anticancer properties [31]. 
 
Anti hyperglycemic activity 
It has been reported in elsewhere, that turmeric extracts were obtained by 
ethanol extraction (E-ext) to yield curcuminoids and sesquiterpenoids, hexane 
extraction (H-ext) to yield sesquiterpenoids, and ethanol extraction from hexane-
extraction residue (HE-ext) to yield curcuminoids. The control group was fed a basal 
diet, while the other groups were fed a diet containing 0.1 or 0.5 g of H-ext or HE-
ext/100 g of diet or 0.2 or 1.0 g of E-ext/100 g of diet for 4 weeks. Although blood 
glucose levels in the control group significantly increased after 4 weeks, feeding of 
0.2 or 1.0 g of E-ext, 0.5 g of H-ext, and 0.5 g of HE-ext/100 g of diet suppressed the 
significant increase in blood glucose levels. Furthermore, E-ext stimulated human 
adipocyte differentiation and these turmeric extracts had human peroxisome 
proliferator-activated receptor-γ (PPAR- γ) ligand-binding activity in a GAL4- 
PPAR- γ chimera assay. Also, curcumin, demethoxycurcumin, bisdemethoxycurcumin, 
and ar-turmerone had PPAR- γ ligand-binding activity. These results indicate that both 
curcuminoids and sesquiterpenoids in turmeric exhibit hypoglycemic effects via 
PPAR- γ activation as one of the mechanisms, and suggest that E-ext including 
curcuminoids and sesquiterpenoids has the additive or synergistic effects of both 
components [32]. 
 
Antiplatelet activity 
The active constituent from turmeric oil was isolated and characterized as 
ar-turmerone by various spectral analyses. At 50% inhibitory concentration (IC50) 
value, ar-turmerone was effective in inhibiting platelet aggregation induced by 
collagen (IC50 14.4 µM) and arachidonic acid (IC5043.6 µM). However, ar-
turmerone had no effect on platelet activating factor or thrombin induced platelet 
aggregation. In comparison, ar-turmerone was significantly more potent platelet 
inhibitor than aspirin against platelet aggregation induced by collagen. These 
results suggested that ar-turmerone could be useful as a lead compound for 
inhibiting platelet aggregation induced by collagen and arachidonic acid [33]. 
 
Antidepressant and Immunostimulant activity 
Ar-turmerone has been also reported as antidepressant agent as at oral dose 
of 2.5, and 5.0 mg/kg, significantly reduced the immobility time of mice in both the 
forced swim test and tail suspension test, but it did not significantly affect the 
ambulatory and total movements of mice. In addition, ar-turmerone decreased the 
corticosterone level in the blood while it increased the levels of 5-HT in cortex, 
striatum, hippocampus, and hypothalamus, the level of NE in striatum and 
hippocampus, the levels of 3-methoxy-4-hydroxyphenylethylglycol (MHPG) and 
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dihydroxyphenylacetic acid (DOPAC) in hypothalamus, the level of 5-
hydroxyindoleacetic acid in striatum, and the level of DA in striatum, hippocampus, 
and hypothalamus. Ar-turmerone also decreased the activity of MAO-A in the frontal 
cortex and hippocampus of mouse brain [34]. Aromatic turmerone (Ar-turmerone) 
was shown to have immunostimulating activities in human peripheral blood 
mononuclear cells by stimulation of peripheral blood mononuclear cells proliferation 
and cytokine production. It also activated caspase cascade by a significant decrease 
of procaspases-3, 8 and 9 [35].  
 
CLINICAL STUDIES 
 
Oral submucous fibrosis, a chronic disease characterized by fibrosis of oral 
mucosa, is a premalignant condition carrying a high risk of malignant 
transformation.  In vitro studies on the effect of turmeric oil and turmeric oleoresin 
on the incidence of micronuclei in lymphocytes from normal healthy subjects 
showed that the test compounds did not cause any increase in the number of 
micronuclei as compared with those found in untreated controls. Further it was 
observed that all three compounds offered protection against benzo[α]pyrene 
induced increase in micronuclei in circulating lymphocytes. In subsequent studies, 
patients suffering from oral submucous fibrosis were given a total oral dose of 
turmeric oil (600 mg TO mixed with 3 g TE/day), turmeric oleoresin (600 mg + 3 g 
TE/day) and 3 g turmeric extract/day as a control for 3 months. It was observed 
that all three treatment modalities decreased the number of micronucleated cells 
both in exfoliated oral mucosal cells and in circulating lymphocytes. Turmeric 
oleoresin was found to be more effective in reducing the number of micronuclei in 
oral mucosal cells but in circulating lymphocytes the decrease in micronuclei was 
comparable in all three groups [12]. This is another clinical study which was 
carried out to evaluate the efficacy of curcumin capsule and turmeric oil in patient 
with oral sobmucous fibrosis both clinically and histopathologically to compare 
them with conventional chemopreventive treatment. After treatment and follow up 
statistically significant improvement was observed in clinical sign and symptoms 
of patient treated with curcumin capsule and turmeric oil when compared to those 
with multinal. Positive changes were also observed in the histopathological 
examination after treatment with curcumin capsule and turmeric oil [11]. 
 
BIOAVAILABILITY 
 
It has been reported that turmeric oil enhances the bioavailability of 
curcumin in human (BCM-95) as well as clinical study is ongoing to assess the 
efficacy and safety of BCM-95 in oral premalignant lesions as well as cervical 
cancers [14]. The major ingredient of turmeric oil determined by GC/MS is 
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reported to be ar-turmerone and its bioavailability was reported to be 13% [2, 5]. 
Such results indicate that turmeric oil has a significant medicinal value which has 
not been exploited yet. The effects of turmerones on curcumin transport were 
evaluated in human intestinal epithelial Caco-2 cells. The roles of turmerones on P-
glycoprotein (P-gp) activities and mRNA expression were also evaluated. Results 
showed that in the presence of α-turmerone and ar-turmerone, the amount of 
curcumin transported into the Caco-2 cells was significantly increased. α-
turmerone and verapamil (P-gp inhibitor) significantly inhibited the efflux of 
rhodamine-123 and digoxin via inhibited the activity of P-gp. It is interesting that 
aromatic turmerone significantly increased the rhodamine-123 efflux and Pgp 
(MDR1 gene) mRNA expression levels. The presence of turmerones did affect the 
absorption of curcumin in vitro. These findings suggest the potential use of 
turmeric extract (including curcumin and turmerones), rather than curcumin alone, 
for treating diseases. In conclusion, the transport of curcumin in Caco-2 cell 
monolayers could be enhanced in the presence of turmerones, which were isolated 
from turmeric crude extract. The two turmerones showed opposite effects on P-gp 
activities: aromatic turmerone inhibited the P-gp activities, whereas α- turmerone 
enhanced P-gp activities as well as up-regulated MDR1, MRP2 and BCRP 
expressions in Caco-2 cells. These findings supported the use of turmeric extract 
(including curcumin and turmerones), other than curcumin alone in cancer patients, 
especially those with colorectal cancers [36]. In view of the long term administration 
required for cancer prevention a Phase I clinical trial of turmeric oil was conducted to 
study the safety and tolerance of turmeric oil in volunteers for a period of 3 months. 
Nine healthy volunteers were tested for haemoglobin, blood counts, liver and kidney 
functions, bleeding and clotting time and serum electrolytes initially and at 1 and 3 
months of treatment. They were administered 0.6 ml of turmeric oil three times a day 
for 1 month and 1 ml in 3 divided doses for 2 months. The acute tolerability study on 
Day 1 was conducted in a Clinical Pharmacology day care Unit. Volunteers were 
daily supervised for turmeric oil intake as well as for any side effects throughout the 
study period. There was no clinical, haematological, renal or hepatic-toxicity of 
turmeric oil. In view of the potential for reversing oral submucous fibrosis, a 
precancerous condition for oral cancer, turmeric oil has been recommended directly 
for a Phase II trial in patients [37]. 
 
TOXICITY 
 
Some studies reported that turmeric oil is safe even at high dose. Food and 
Drug Administration (FDA) approved turmeric oil usage as food additive and is 
listed as Generally Recognized As Safe (GRAS), while the FDAs GRAS list does 
not include the dosage of turmeric oil. Turmeric oil is usually used in aroma 
therapy and the recommended dose is 1–2 drops/day. Acute administration of 
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turmeric oil was done as single dose up to 5 g of turmeric oil per kg body weight 
and subchronic toxicity study for thirteen weeks was done by daily oral 
administration of turmeric oil at doses 0.1, 0.25 and 0.5 g/kg body weight in wistar 
rats. There were not found any mortality, adverse clinical signs or changes in body 
weight, water and food consumption during acute as well as subchronic toxicity 
studies. Indicators of hepatic function such as aspartate aminotransferase, alanine 
amino transferase and alkaline phosphatase were unchanged in treated animals 
compared to untreated animals. Oral administration of turmeric oil for 13 weeks 
did not alter total cholesterol, triglycerides, and markers of renal function, serum 
electrolyte parameters and histopathology of tissues. Turmeric oil did not produce 
any mutagenicity to Salmonella typhimurium TA-98, TA-100, TA-102 and TA-
1535 with or without metabolic activation. Administration of turmeric oil to rats (1 
g/kg b.wt.) for 14 days did not produce any chromosome aberration or micronuclei 
in rat bone marrow cells and did not produce any DNA damage as seen by comet 
assay confirming the non toxicity of turmeric oil. Anti-arthritic evaluation of 
turmeric oil in mice was carried out at doses of 560 mg/kg body weight [7]. 
Turmeric oil (0.1–3 mg/plate) did not produce any revertants during Ames test, 
indicating that there was no significant dose related mutagenicity of the turmeric 
oil either with or without metabolic activation. Genotoxic substances are 
potentially known to be mutagenic or carcinogenic. Exposure of cells to genotoxic 
substances damage chromosomes of the mitotic spindle leading to the formation of 
micronuclei. Genotoxic studies of turmeric oil such as micronuclei formation, 
chromosomal aberrations and genomic DNA damage analysis by comet assay have 
revealed that there was no genotoxic effect after 2 weeks oral administration of 1 
g/kg body weight turmeric oil [38]. 
 
CONCLUSION 
 
As like many other medicinal plants turmeric also produces structurally 
and functionally diverse bioactive secondary plant metabolites, not all of which can 
be extracted by a single solvent or extraction procedure. Moreover, therapeutically 
interesting bioactivity profile of a given plant extract is not only a resultant of the 
combined effects of all bioactive ingredients present in it, but also depends on its 
treatment regimen used to define its activity profile. Complexities arising from 
these facts clearly indicate that translation of traditional knowledge on medicinal 
uses of turmeric or of any other medicinal plant, in terms of modern medical 
sciences is possible only when the plant is considered as a whole, and its diverse 
types of extracts are tested in a battery of therapy relevant animal models. 
Hereupon, we have paid attention to the pharmacological activity profiles of the 
turmeric oil. Turmeric oil contains several interesting pharmacological activities. 
Due to lipophilic in nature it also facilitates the transportation of curcuminoids 
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across the membrane and increases its bioavailability. Several reports confirms the 
fact that turmeric oil is safe even at it high dose. Even then turmeric oil is not 
explored as potent therapeutic agent. It is now well established that all chronic 
diseases or illnesses, always causes mental health problems, and that bi directional 
interactions between mental health problems and physical health is a common 
feature of almost all socioeconomically important health problems. Unfortunately, 
even today, modern medicinal phytochemists and pharmacologists pay little 
attention to these facts and continue to explore traditionally known medicinal 
plants as sources for structurally and functionally novel therapeutic lead molecules 
only. Lessons learned and experiences gained from extensive efforts made since 
decades strongly suggest that turmeric oil could be a valuable and potential 
therapeutic agent. 
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IZVOD 
 
Kurkuma (Curcuma longa), lekovita biljka iz porodice Zingiberaceae, 
široko je rasprostranjena širom Indije. Njeno etarsko ulje, produkat sekundarnog 
metabolizma, dobija se destilacijom vodenom parom iz rizoma. Ulje je po prirodi 
lipofilno i ispoljava veliki terapeutski potencijal.Ulje kurkume se uglavnom sastoji 
od ar-turmerona i β-turmerona. Tokom poslednjih par decenija publikovani su 
brojni radovi na temu terapijski zanimljivih farmakoloških osobina kurkume i 
njenih sekundarnih metabolita. Skorašnji napori da se istraži farmakološki profil i 
mehanizam delovanja kurkume otkrili su izuzetno širok spektar farmakološke 
aktivnosti kurkuma ulja. Sada je već dobro poznato da se aditivne ili sinergijske 
interakcije među različitim kombinacijama fitohemijskih jedinjenja smatraju 
benefitima vegetarijanske ishrane i biljnih lekova za ljudsko zdravlje, i preporučuju 
se odgovarajuće kombinacije takvih jestivih fitohemikalija u svakodnevnoj ishrani 
kao i njihovo korišćenje u prevenciji i lečenju različitih zdravstvenih problema. 
Kritička analiza raspoloživih prekliničkih i kliničkih informacija o ulju kurkume 
snažno sugeriše kako je ono farmakološki polivalentno i poseduje razna 
farmakoloških svojstava. Cilj ovog rada je da sumira i kritički analizira prikupljene 
podatke o ulju kurkume i ukaže na mogućnosti racionalnijeg iskorišćavanja 
njegovog terapeutskog potencijala radi otkrivanja novih terapijskih mogućnosti ili 
dobijanja farmakološki standardizovanih fito-preparata.  
 
Ključne reči: Curcuma longa, etrasko ulje kurkume, lipofilno, fitofarmaceutika. 
 
 
 
 
 
 
 
 
 
 
 
